Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

Leukemia volume 28, pages 1736–1738 (2014)Cite this article

Subjects

The BCR-ABL-negative myeloproliferative neoplasm, primary or post-ET/PV myelofibrosis (MF), is chronic hematological malignancy with a median survival of <5 years.1

Allogeneic stem cell transplantation (ASCT) is a curative therapy for MF, and is recommended for patients with a life expectancy of <5 years.2, 3

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary MF based on a study of the International Working Group for MF Research and Treatment. Blood 2009; 113: 2895–2901.

    Article  CAS  Google Scholar 

  2. Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005; 20: 879–889.

    CAS  Google Scholar 

  3. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.

    Article  Google Scholar 

  4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passeg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  Google Scholar 

  6. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med 2012; 366: 787–798.

    Article  CAS  Google Scholar 

  7. Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Eng J Med 2012; 366: 799–807.

    Article  CAS  Google Scholar 

  8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013; 98: 1865–1871.

    Article  CAS  Google Scholar 

  9. Ciurea SO, Sadeqi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing reduced intensity allogeneic stem cell transplantation. Br J Hematol 2008; 141: 80–83.

    Article  Google Scholar 

  10. Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157: 75–85.

    Article  Google Scholar 

  11. Massa M, Rosti V, Campanelli R, Fois G, Barosi G . Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis reated with ruxolitinib. Leukemia 2014; 28: 449–451.

    Article  CAS  Google Scholar 

  12. Goldberg RA, Reichel E, Oshry LJ . Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013; 369: 681–683.

    Article  CAS  Google Scholar 

  13. Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G . Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225–227.

    Article  CAS  Google Scholar 

  14. Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 2014; 49: 179–184.

    Article  CAS  Google Scholar 

  15. Robin M, Francois S, Huynh A, Cassinat B, Bay JO, Cornillon J et alRuxolitinib before allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored by GOELAMS-FIM in collaboration with the SFGMTC, 55th ASH Annual Meeting and Exposition, New Orleans, LA, pp 7–10 December 2013.

Download references

Author information

Author notes

  1. T Stübig and H Alchalby: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    T Stübig, H Alchalby, T Zabelina, C Wolschke, F Ayuk & N Kröger

  2. Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany

    M Ditschkowski

  3. Medical Clinic III, Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany

    D Wolf

  4. Department of Hematology/Oncology, University Hospital Göttingen, Göttingen, Germany

    G Wulf

Authors
  1. T Stübig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Alchalby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Ditschkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Wulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Wolschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Ayuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Kröger.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Authors contributions

TS and HA analyzed data and wrote the manuscript, MD DW, GW, CW and FA contributed patients and approved the manuscript, TZ analyzed the data and approved the manuscript, NK designed the study, analyzed the data and wrote the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stübig, T., Alchalby, H., Ditschkowski, M. et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 28, 1736–1738 (2014). https://doi.org/10.1038/leu.2014.86

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.86

This article is cited by

Search

Advanced search

Quick links